Seventure Partners Life Sciences Business Update 2016
Paris, France – 5 May 2016 - Seventure Partners (‘Seventure’), one of Europe’s leaders in financing innovation, is pleased to provide a business update for the first four months of 2016.
Recent appointments and a number of positive milestones, both financial and in partnering collaborations from its portfolio, have meant a strong start to the year for Seventure, leading the way into a successful Q2 2016.
Seventure Partners’ News
Seventure Partners closed the final round of its €160M Health for Life Capital vehicle, the world’s first investment fund to anticipate the microbiome revolution in the fields of health and nutrition, in December 2015. As Seventure Partners continues to invest in companies working at the cutting edge of research in these areas, it has appointed Professor Denise Kelly as an Investment Advisor and Oxana Kukhaneva as Venture Partner. The appointments reflect Seventure Partners' dedication to growing the team which now focuses on the fields of food, nutrition and human health across Europe and North America.
Portfolio Company News
Enterome, a pioneer in the development of therapeutic solutions based on the gut microbiome, entered into two collaborations in the first quarter, announcing an agreement with Takeda to focus on microbiome targets across multiple gastrointestinal disorders as well as an agreement with Johnson & Johnson Innovation which will aim to discover new targets and therapeutics for Crohn’s Disease. In April it raised €14.5 million in a Series C financing round, which was led by Seventure, Lundbeckfond Ventures and included new investor, Nestlé Health Science. The funds will be used to advance the development of its lead candidate EB8018, a potential treatment for inflammatory bowel disease, into clinical studies this year.
Following Seventure’s launch of MaaT Pharma last year, the company announced that led a €10 million fundraising in March, along with the French National Institute for Agricultural Research (INRA), and new investment partners CM-CIC Innovation and Biocodex. Funds raised will be used to pursue the development of the world’s first microbiotherapy.
In April Cambrooke Therapeutics, Inc. closed a Series C investment round, led by Seventure and Galen Partners. The funds will be used to aid the Company’s global expansion strategy and enter into other disease states.
Seventure and Pontifax led a €5.8 million Series A fundraising round in TargEDys which closed in April. TargEDys will use the funds to move into human clinical trials with products that harness the microbiome’s ability to regulate appetite and restore metabolic health.
Events
Over the first four months of 2016, Seventure has been actively involved at events across the world.
• At the 3rd Microbiome R&D and Business Collaboration Forum: Europe, held in London, Eric de la Fortelle, Venture Partner, joined speakers from Microbiome Insights, Inc., MPM Capital and Inventages Venture Capital for a panel discussion on venture capital and microbiome investment
• Professor Denise Kelly, Investment Advisor, was a panelist at the 2nd Translational Microbiome Conference in Boston, 20-21 March, joined by speakers from Second Genome, Vedanta Biosciences, Digitalis Ventures, Atlas Venture and Flagship Venture Labs
• Isabelle de Cremoux, CEO, discussed the financial perspectives on the emergence of a microbiome-based industry at Better Foods for Better Health 5th Edition – Microbiota & Health: The Challenges of a Promising Approach Reflecting its leadership position and to support its strong network, Seventure Partners will be speaking at the following events over the rest of H2:
• Professor Denise Kelly at Food-Microbiome Interaction: Implications for Health and Disease Conference - London, 10-12 May
• Isabelle de Cremoux at Labiotech Refresh – Berlin, 24 May
• Isabelle de Cremoux at Microbiome Drug Development Summit – Boston, 28 May
• Eric de la Fortelle will also be speaking at the Tech Tour Healthtech Summit – Lausanne, 21 June
Isabelle de Cremoux, CEO of Seventure Partners, said: “The first few months of 2016 has been exceptional in terms of our growth and in the quality of the companies in which we have invested. We continue to drive forward with investments into life sciences companies of the highest calibre and we look forward to an equally successful second quarter.”
- ENDS -
Notes To Editors
About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.
In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
For more details: www.seventure.com
Recent appointments and a number of positive milestones, both financial and in partnering collaborations from its portfolio, have meant a strong start to the year for Seventure, leading the way into a successful Q2 2016.
Seventure Partners’ News
Seventure Partners closed the final round of its €160M Health for Life Capital vehicle, the world’s first investment fund to anticipate the microbiome revolution in the fields of health and nutrition, in December 2015. As Seventure Partners continues to invest in companies working at the cutting edge of research in these areas, it has appointed Professor Denise Kelly as an Investment Advisor and Oxana Kukhaneva as Venture Partner. The appointments reflect Seventure Partners' dedication to growing the team which now focuses on the fields of food, nutrition and human health across Europe and North America.
Portfolio Company News
Enterome, a pioneer in the development of therapeutic solutions based on the gut microbiome, entered into two collaborations in the first quarter, announcing an agreement with Takeda to focus on microbiome targets across multiple gastrointestinal disorders as well as an agreement with Johnson & Johnson Innovation which will aim to discover new targets and therapeutics for Crohn’s Disease. In April it raised €14.5 million in a Series C financing round, which was led by Seventure, Lundbeckfond Ventures and included new investor, Nestlé Health Science. The funds will be used to advance the development of its lead candidate EB8018, a potential treatment for inflammatory bowel disease, into clinical studies this year.
Following Seventure’s launch of MaaT Pharma last year, the company announced that led a €10 million fundraising in March, along with the French National Institute for Agricultural Research (INRA), and new investment partners CM-CIC Innovation and Biocodex. Funds raised will be used to pursue the development of the world’s first microbiotherapy.
In April Cambrooke Therapeutics, Inc. closed a Series C investment round, led by Seventure and Galen Partners. The funds will be used to aid the Company’s global expansion strategy and enter into other disease states.
Seventure and Pontifax led a €5.8 million Series A fundraising round in TargEDys which closed in April. TargEDys will use the funds to move into human clinical trials with products that harness the microbiome’s ability to regulate appetite and restore metabolic health.
Events
Over the first four months of 2016, Seventure has been actively involved at events across the world.
• At the 3rd Microbiome R&D and Business Collaboration Forum: Europe, held in London, Eric de la Fortelle, Venture Partner, joined speakers from Microbiome Insights, Inc., MPM Capital and Inventages Venture Capital for a panel discussion on venture capital and microbiome investment
• Professor Denise Kelly, Investment Advisor, was a panelist at the 2nd Translational Microbiome Conference in Boston, 20-21 March, joined by speakers from Second Genome, Vedanta Biosciences, Digitalis Ventures, Atlas Venture and Flagship Venture Labs
• Isabelle de Cremoux, CEO, discussed the financial perspectives on the emergence of a microbiome-based industry at Better Foods for Better Health 5th Edition – Microbiota & Health: The Challenges of a Promising Approach Reflecting its leadership position and to support its strong network, Seventure Partners will be speaking at the following events over the rest of H2:
• Professor Denise Kelly at Food-Microbiome Interaction: Implications for Health and Disease Conference - London, 10-12 May
• Isabelle de Cremoux at Labiotech Refresh – Berlin, 24 May
• Isabelle de Cremoux at Microbiome Drug Development Summit – Boston, 28 May
• Eric de la Fortelle will also be speaking at the Tech Tour Healthtech Summit – Lausanne, 21 June
Isabelle de Cremoux, CEO of Seventure Partners, said: “The first few months of 2016 has been exceptional in terms of our growth and in the quality of the companies in which we have invested. We continue to drive forward with investments into life sciences companies of the highest calibre and we look forward to an equally successful second quarter.”
- ENDS -
Notes To Editors
About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.
In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
For more details: www.seventure.com